We are live on !
Find out more
Longview Partners Portfolio holdings
AUM
$6.16B
Turnover
15.38%
1-Year Est. Return
3.55%
Longview Partners is a specialist global equity manager that holds a concentrated portfolio of world stocks, using the same philosophy since it started in 2001. It looks for high-quality businesses that can build value steadily over time, wants a margin of safety on price, and relies on picking individual stocks rather than steering the overall portfolio. Its clients are institutions, and Northill Capital is its majority shareholder.
This Fund
S&P 500
This Quarter Est. Return
+3.97%
1 Year Est. Return
+3.55%
3 Year Est. Return
+35.76%
5 Year Est. Return
+55.83%
10 Year Est. Return
+255.17%
AUM
$19.2B
AUM Growth
+$125M
(+0.65%)
Cap. Flow
-$574M
Cap. Flow % of AUM
Cap. Flow %
-2.99%
Top 10 Holdings %
Top 10 Hldgs %
51.61%
Holding
25
New
–
Increased
1
Reduced
24
Closed
–
Avg Time Held
3.1
years
Top 10 Avg Time Held
0.6
years
Top 20 Avg Time Held
3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$93.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fiserv Inc
FISV
|
+$203M |
| 2 |
W.W. Grainger
GWW
|
+$166M |
| 3 |
Dollar General
DG
|
+$57M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$40.5M |
| 5 |
TMX
Terminix Global Holdings, Inc.
TMX
|
+$26.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 37.84% |
| 2 | Financials | 23.34% |
| 3 | Industrials | 16.59% |
| 4 | Technology | 13.07% |
| 5 | Consumer Staples | 5.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
W.W. Grainger
GWW
$69.4B
| $1.09B | 5.68% |
3,534,534
-555,365
| -14% | -$166M |
2015 Q4
10 quarters
|
|
2
Fidelity National Information Services
FIS
$15.5B
| $1.07B | 5.56% |
10,062,755
-150,247
| -1% | -$15.3M |
2013 Q2
20 quarters
|
|
3
Henry Schein
HSIC
$9.7B
| $1.01B | 5.24% |
17,651,676
-55,491
| -0.3% | -$3.13M |
2018 Q1
1 quarter
|
|
4
UnitedHealth
UNH
$358B
| $999M | 5.2% |
4,072,098
-56,812
| -1% | -$13.6M |
2014 Q1
17 quarters
|
|
5
HCA Healthcare
HCA
$105B
| $979M | 5.1% |
9,542,360
-123,602
| -1% | -$12.5M |
2013 Q3
19 quarters
|
|
|
6
Dollar General
DG
$30.3B
| $978M | 5.09% |
9,921,543
-593,121
| -6% | -$57M |
2017 Q2
4 quarters
|
|
7
IQVIA
IQV
$45.7B
| $967M | 5.03% |
9,683,965
-105,655
| -1% | -$10.6M |
2016 Q4
6 quarters
|
|
8
Bank of New York Mellon
BNY
$103B
| $952M | 4.96% |
17,649,013
-171,771
| -1% | -$9.48M |
2013 Q2
20 quarters
|
|
9
Emerson Electric
EMR
$93.5B
| $940M | 4.9% |
13,598,373
-145,712
| -1% | -$10.2M |
2015 Q1
13 quarters
|
|
10
Wells Fargo
WFC
$258B
| $932M | 4.86% |
16,817,682
-151,045
| -0.9% | -$8.09M |
2013 Q2
20 quarters
|
|
11
Willis Towers Watson
WTW
$30.7B
| $930M | 4.84% |
6,131,312
-59,420
| -1% | -$9.04M |
2016 Q2
8 quarters
|
|
12
Pfizer
PFE
$167B
| $926M | 4.82% |
26,897,431
-290,502
| -1% | -$9.9M |
2013 Q2
20 quarters
|
|
13
Aon
AON
$71.1B
| $926M | 4.82% |
6,748,667
-172,930
| -2% | -$24.4M |
2013 Q2
20 quarters
|
|
14
Oracle
ORCL
$403B
| $866M | 4.51% |
19,653,249
-212,062
| -1% | -$9.8M |
2013 Q2
20 quarters
|
|
15
Zimmer Biomet
ZBH
$20.2B
| $864M | 4.5% |
7,981,361
-96,017
| -1% | -$10.5M |
2015 Q3
11 quarters
|
|
16
State Street
STT
$47.5B
| $742M | 3.87% |
7,972,455
-80,216
| -1% | -$7.95M |
2017 Q1
5 quarters
|
|
|
17
Thermo Fisher Scientific
TMO
$267B
| $667M | 3.47% |
3,219,655
-190,875
| -6% | -$40.5M |
2015 Q3
11 quarters
|
|
18
Parker-Hannifin
PH
$122B
| $627M | 3.27% |
4,023,212
-35,185
| -0.9% | -$6M |
2015 Q2
12 quarters
|
|
19
Medtronic
MDT
$129B
| $596M | 3.11% |
6,965,895
-63,585
| -0.9% | -$5.31M |
2018 Q1
1 quarter
|
|
|
TMX
20
DELISTED
Terminix Global Holdings, Inc.
TMX
| $528M | 2.75% |
13,264,639
-703,411
| -5% | -$26.1M |
2016 Q2
8 quarters
|
|
21
Omnicom Group
OMC
$24.3B
| $491M | 2.56% |
6,436,593
-60,496
| -0.9% | -$4.47M |
2014 Q1
17 quarters
|
|
|
22
Fiserv Inc
FISV
$33.9B
| $359M | 1.87% |
4,846,334
-2,791,258
| -37% | -$203M |
2013 Q2
20 quarters
|
|
23
TJX Companies
TJX
$150B
| $290M | 1.51% |
6,100,956
-62,878
| -1% | -$2.76M |
2018 Q1
1 quarter
|
|
|
AGN
24
DELISTED
Allergan plc
AGN
| $262M | 1.36% |
1,570,931
+580,808
| +59% | +$93.2M |
2018 Q1
1 quarter
|
|
25
Arrow Electronics
ARW
$10.1B
| $218M | 1.14% |
2,896,179
-26,312
| -0.9% | -$2M |
2013 Q2
20 quarters
|
|
Similar funds
EQF
Longview Partners's Q2 2018 Portfolio in Review
As of Q2 2018, Longview Partners held 25 positions worth $19.2B, up 0.65% from $19.1B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Trading was light in Q2 2018: portfolio turnover was 0%. Longview Partners opened no new positions and made no exits, leaving the 25-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 36% a quarter earlier, followed by Financials and Industrials.
- Longview Partners added most to Allergan plc in Q2 2018, an estimated $93.2M increase.
- Longview Partners's biggest Q2 2018 reduction was Fiserv Inc, cutting an estimated $203M.
- Longview Partners's ten largest holdings make up 52% of its $19.2B portfolio in Q2 2018.
- Longview Partners opened 0 new positions and closed 0 in Q2 2018.
- Longview Partners's portfolio value rose 0.65% quarter-over-quarter to $19.2B.
Based on Longview Partners's 13F filing for Q2 2018, filed 1 Aug 2018.